Oncology Venture has USD 8.7 million deficit after nine months

Biotech company Oncology Venture has significantly increased its deficit in the third quarter, and for the first three quarters as a whole, but the company's finances are comfortable going into 2020, says the new finance director.

Henrik Moltke, finance director at Oncology Venture Photo: PR / Oncology Venture

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles